Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion: A human study

Saverio Dragoni, Tommaso Gori, Giuseppe Di Stolfo, Silvia Sicuro, Sandra Forconi, John D. Parker

Research output: Contribution to journalArticle

Abstract

Nitric oxide synthase (NOS) uncoupling is a condition of increased production of superoxide anion associated with a decreased production of nitric oxide (NO) by this enzyme. Folic acid can prevent and/or reverse NOS uncoupling in the setting of diabetes, smoking, hypercholesterolemia, and nitrate tolerance. Whereas animal studies showed a protective effect of folic acid in ischemia and reperfusion (IR) injury, no study tested whether folic acid administration limits IR-induced endothelial dysfunction in humans. In a double-blind, parallel study, 20 healthy young male volunteers were randomized to receive folic acid, 10 mg/d for 7 days, or matching placebo. At the end of the treatment period, endothelium-dependent, flow-mediated dilation (FMD) of the radial artery was measured before and after IR injury (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion). There was no difference at baseline between groups in any variable. In the placebo group, IR significantly blunted FMD (before IR, 6.7 ± 1.0%; after IR, 1.5 ± 1.3%, P <0.01). A similar effect was observed in the folic acid group (before IR, 6.3 ± 1.1%; after IR, 2.1 ± 1.0%, P = ns compared with placebo). As opposed to animal studies, high-dose folic acid does not protect the vascular endothelium from IR injury in humans.

Original languageEnglish
Pages (from-to)494-497
Number of pages4
JournalJournal of Cardiovascular Pharmacology
Volume46
Issue number4
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Folic Acid
Reperfusion
Ischemia
Reperfusion Injury
Placebos
Nitric Oxide Synthase
Dilatation
Radial Artery
Brachial Artery
Vascular Endothelium
Hypercholesterolemia
Double-Blind Method
Superoxides
Nitrates
Endothelium
Volunteers
Nitric Oxide
Smoking
Enzymes

Keywords

  • Folic acid
  • Ischemia-reperfusion injury
  • Nitric oxide synthase

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion : A human study. / Dragoni, Saverio; Gori, Tommaso; Di Stolfo, Giuseppe; Sicuro, Silvia; Forconi, Sandra; Parker, John D.

In: Journal of Cardiovascular Pharmacology, Vol. 46, No. 4, 10.2005, p. 494-497.

Research output: Contribution to journalArticle

Dragoni, Saverio ; Gori, Tommaso ; Di Stolfo, Giuseppe ; Sicuro, Silvia ; Forconi, Sandra ; Parker, John D. / Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion : A human study. In: Journal of Cardiovascular Pharmacology. 2005 ; Vol. 46, No. 4. pp. 494-497.
@article{21b5c74c32da4545bab97191ab9251a0,
title = "Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion: A human study",
abstract = "Nitric oxide synthase (NOS) uncoupling is a condition of increased production of superoxide anion associated with a decreased production of nitric oxide (NO) by this enzyme. Folic acid can prevent and/or reverse NOS uncoupling in the setting of diabetes, smoking, hypercholesterolemia, and nitrate tolerance. Whereas animal studies showed a protective effect of folic acid in ischemia and reperfusion (IR) injury, no study tested whether folic acid administration limits IR-induced endothelial dysfunction in humans. In a double-blind, parallel study, 20 healthy young male volunteers were randomized to receive folic acid, 10 mg/d for 7 days, or matching placebo. At the end of the treatment period, endothelium-dependent, flow-mediated dilation (FMD) of the radial artery was measured before and after IR injury (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion). There was no difference at baseline between groups in any variable. In the placebo group, IR significantly blunted FMD (before IR, 6.7 ± 1.0{\%}; after IR, 1.5 ± 1.3{\%}, P <0.01). A similar effect was observed in the folic acid group (before IR, 6.3 ± 1.1{\%}; after IR, 2.1 ± 1.0{\%}, P = ns compared with placebo). As opposed to animal studies, high-dose folic acid does not protect the vascular endothelium from IR injury in humans.",
keywords = "Folic acid, Ischemia-reperfusion injury, Nitric oxide synthase",
author = "Saverio Dragoni and Tommaso Gori and {Di Stolfo}, Giuseppe and Silvia Sicuro and Sandra Forconi and Parker, {John D.}",
year = "2005",
month = "10",
doi = "10.1097/01.fjc.0000177983.68563.d1",
language = "English",
volume = "46",
pages = "494--497",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion

T2 - A human study

AU - Dragoni, Saverio

AU - Gori, Tommaso

AU - Di Stolfo, Giuseppe

AU - Sicuro, Silvia

AU - Forconi, Sandra

AU - Parker, John D.

PY - 2005/10

Y1 - 2005/10

N2 - Nitric oxide synthase (NOS) uncoupling is a condition of increased production of superoxide anion associated with a decreased production of nitric oxide (NO) by this enzyme. Folic acid can prevent and/or reverse NOS uncoupling in the setting of diabetes, smoking, hypercholesterolemia, and nitrate tolerance. Whereas animal studies showed a protective effect of folic acid in ischemia and reperfusion (IR) injury, no study tested whether folic acid administration limits IR-induced endothelial dysfunction in humans. In a double-blind, parallel study, 20 healthy young male volunteers were randomized to receive folic acid, 10 mg/d for 7 days, or matching placebo. At the end of the treatment period, endothelium-dependent, flow-mediated dilation (FMD) of the radial artery was measured before and after IR injury (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion). There was no difference at baseline between groups in any variable. In the placebo group, IR significantly blunted FMD (before IR, 6.7 ± 1.0%; after IR, 1.5 ± 1.3%, P <0.01). A similar effect was observed in the folic acid group (before IR, 6.3 ± 1.1%; after IR, 2.1 ± 1.0%, P = ns compared with placebo). As opposed to animal studies, high-dose folic acid does not protect the vascular endothelium from IR injury in humans.

AB - Nitric oxide synthase (NOS) uncoupling is a condition of increased production of superoxide anion associated with a decreased production of nitric oxide (NO) by this enzyme. Folic acid can prevent and/or reverse NOS uncoupling in the setting of diabetes, smoking, hypercholesterolemia, and nitrate tolerance. Whereas animal studies showed a protective effect of folic acid in ischemia and reperfusion (IR) injury, no study tested whether folic acid administration limits IR-induced endothelial dysfunction in humans. In a double-blind, parallel study, 20 healthy young male volunteers were randomized to receive folic acid, 10 mg/d for 7 days, or matching placebo. At the end of the treatment period, endothelium-dependent, flow-mediated dilation (FMD) of the radial artery was measured before and after IR injury (15 minutes of ischemia at the level of the brachial artery followed by 15 minutes of reperfusion). There was no difference at baseline between groups in any variable. In the placebo group, IR significantly blunted FMD (before IR, 6.7 ± 1.0%; after IR, 1.5 ± 1.3%, P <0.01). A similar effect was observed in the folic acid group (before IR, 6.3 ± 1.1%; after IR, 2.1 ± 1.0%, P = ns compared with placebo). As opposed to animal studies, high-dose folic acid does not protect the vascular endothelium from IR injury in humans.

KW - Folic acid

KW - Ischemia-reperfusion injury

KW - Nitric oxide synthase

UR - http://www.scopus.com/inward/record.url?scp=26044452063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26044452063&partnerID=8YFLogxK

U2 - 10.1097/01.fjc.0000177983.68563.d1

DO - 10.1097/01.fjc.0000177983.68563.d1

M3 - Article

C2 - 16160603

AN - SCOPUS:26044452063

VL - 46

SP - 494

EP - 497

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -